
    
      The objectives of this trial, conducted in thrombocytopenic patients with modified World
      Health Organization (WHO) Grade 1* or 2 bleeding, assessing the safety of infusing increasing
      doses of allogeneic Thrombosomes in WHO bleeding and measures of coagulation.
    
  